| This week's sponsor is Premier Research. | | | Tackling gene therapy's biggest challenges
Gene therapy holds great promise, but despite revolutionary advances, a clear path from bench to bedside remains elusive. Download the white paper for more tips on seizing this unprecedented opportunity. Premier Research. Built for biotech.
Visit us at BIO International, Booth 4049 to learn more. |
Today's Rundown Vertex makes $420M preclinical play for DMD gene editing field Grail finds a new CEO in former Juno chief Hans Bishop BIO: In conversation with Emil Kakkis, Ultragenyx CEO [Sponsored] How to Make the Most of Your Clinical Trial Data—All of it BIO: In conversation with Helen Torley, CEO of Halozyme BIO: Meet Refuge Biotech, the company developing ‘intelligent’ cell therapies Headed for the exit: Sanofi CEO Brandicourt to retire, Novartis' Hudson steps in EuroBiotech Report—Woodford's woes, Bayer-Arvinas, AstraZeneca, Sanofi and Novartis FiercePharmaAsia—China audits for Big Pharma; Takeda's phase 3 trial failure Chutes & Ladders—Bristol-Myers unveils post-Celgene R&D team Featured Story | | | Friday, June 7, 2019 Vertex is paying $420 million upfront to go after the muscular dystrophy market. The outlay will give Vertex ownership of Exonics and expand its deal with CRISPR Therapeutics, setting it up to use gene editing to treat Duchenne muscular dystrophy and myotonic dystrophy type 1. |
|
|
| Thank you to Lonza for sponsoring this week's coverage of BIO. |
Top Stories Friday, June 7, 2019 Just weeks after securing a breakthrough designation, honing its cancer detection strategy and presenting promising early results, Grail is bringing on a new CEO as it inches its blood test toward the market. Former Juno Therapeutics helmsman Hans Bishop will pick up Grail’s quest to develop a simple, pan-cancer liquid biopsy. Friday, June 7, 2019 PHILADELPHIA—When Emil Kakkis started Ultragenyx in 2010, it was a company of two. Nine years later, Kakkis reflected on how he’s preserved the culture of a small biotech even as the rare disease company expands beyond 700 staffers. Monday, June 3, 2019 Pharma and biopharma have endless data at their disposal. Why aren't they using it? Here's how to make the most of your data for clinical success. Friday, June 7, 2019 Halozyme CEO Helen Torley discusses the company’s two-pronged strategy, what’s up next for the company and why biotechs are filing IPOs earlier and earlier. Friday, June 7, 2019 Refuge is working on “intelligent” T cell therapies that can “think for themselves and react to their environment." Its lead candidate is a HER2-based treatment for solid cancers, an arena in which T cell therapies have seen limited success. Friday, June 7, 2019 Sanofi CEO Olivier Brandicourt has worked to reshape the drugmaker during his four-plus years at the company, but problems remain. Brandicourt is now retiring, and Novartis' Paul Hudson will take the job. Thursday, June 6, 2019 In this week's EuroBiotech Report, Woodford suspends flagship fund, Bayer inks protein degradation deal and AstraZeneca talks up approach to cancer. Friday, June 7, 2019 Eli Lilly and other multinational drugmakers will be audited in China. Plus, Takeda entered an R&D collab and disclosed a trial failure. And more. Friday, June 7, 2019 Bristol-Myers unveils team to lead R&D after Celgene deal closes; GE Healthcare executive to lead dermatology biotech LEO Pharma; and after 31 years at Merck, Schechter jumps for LabCorp CEO job. Those moves plus more hirings, firings and retirings throughout the industry. | This week's sponsor is LabConnect. | | |
LabConnect offers innovative project & data management services connecting samples to data. We customize services to meet the unique needs of clients and their clinical studies. LabConnect is your connection to confidence. Contact us to learn more. |
Resources Sponsored by: Reprints Desk, Inc. Get 5 quick tips for faster research and better results! Sponsored by: Blue Latitude Health In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report. Sponsored by: Patheon, by Thermo Fisher Scientific Increase Safety & Flexibility with Flow Chemistry Sponsored by: Veeva IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now. Sponsored by: WCG Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! |
